RxDoctor Payments Data

Leandra Smith

Family · Hazard, KYNPI 1154966703

Payments from drug & device makers

$405in general payments, 2019–2025

Across 30 payments — averaging $13.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$79
  • Lilly USA, LLC$58
  • Corcept Therapeutics$37
  • Exact Sciences$35
  • Pfizer$35
  • Genentech USA, Inc.$25
  • plus $135 from 8 others

What the payments were for

  • Food & beverage$405100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$405 in reported general payments places this provider in the 45th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,211
Medicare patients
23
Services billed
57

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide100$108,410
JardianceEmpagliflozin63$77,240
JanuviaSitagliptin Phosphate30$45,746
OzempicSemaglutide43$41,394
EliquisApixaban26$34,667
TrulicityDulaglutide26$26,893
FarxigaDapagliflozin Propanediol17$22,183
MyrbetriqMirabegron16$12,667
VascepaIcosapent Ethyl14$10,234
Breo ElliptaFluticasone/Vilanterol16$8,002
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$5,967
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$4,610
Albuterol Sulfate HfaAlbuterol Sulfate134$4,437
ShingrixVaricella-Zoster Ge/As01b/Pf20$3,846
SymbicortBudesonide/Formoterol Fumarate11$2,669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$58$135,303126 claims
MerckJanuvia$16$45,74630 claims
Novo NordiskOzempic$23$41,39443 claims
PfizerEliquis$35$34,66726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 4,374 family providers in Kentucky.

Other family in Hazard

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →